PRAX
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Praxis Precision Medicines, Inc.
- Nom
- Praxis Precision Medicines, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $7.1B
- Employés
- 168
- PDG
- Marcio Silva De'Souza
- Site web
- https://www.praxismedicines.com
- Marché
- ACADADXNAVXLAXSMDNLINBIX
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-07-30 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-07-29 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-30 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
PRAX presents a deeply concerning financial profile: despite strong liquidity (score 85), the near-zero fundamental trend score (15) reflects a pre-revenue, cash-burning company with no path to near-term profitability.
The first sentence of the analysis written for PRAX on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 10.22 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | -1682.0% | -3445.8% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | -2137.5% | -5037.9% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | -2133.3% | -5020.2% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | -2340.3% | -5164.4% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | -2137.5% | -5037.9% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | -2137.5% | -5037.9% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | -2137.5% | -5037.9% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | -2137.5% | -5037.9% | 0.0% | 0.0% | |
| Current Ratio | 10.221 | 10.769 | 5.390 | 3.227 | 7.478 | |
| Quick Ratio | 10.221 | 10.769 | 5.390 | 3.227 | 7.478 | |
| Solvency Ratio | -5.071 | -4.845 | -6.721 | -5.474 | -3.979 | |
| Cash Ratio | 5.978 | 5.736 | 5.162 | 1.794 | 3.609 | |
| Price To Earnings Ratio | -21.865 | -7.538 | -1.192 | -0.515 | -5.012 | |
| Price To Earnings Growth Ratio | -0.683 | 0.166 | 0.016 | -0.029 | 0.116 | |
| Forward Price To Earnings Growth Ratio | -0.683 | 0.166 | 0.016 | -0.029 | 0.116 | |
| Price To Earnings Diluted Ratio | -21.865 | -7.538 | -1.192 | -0.515 | -5.012 | |
| Price To Earnings Diluted Growth Ratio | -0.683 | 0.166 | 0.016 | -0.029 | 0.116 | |
| Price To Book Ratio | 7.554 | 3.094 | 2.109 | 1.442 | 3.335 | |
| Price To Sales Ratio | 0.000 | 161.126 | 60.041 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -26.625 | -10.459 | -1.321 | -0.591 | -6.659 | |
| Price To Operating Cash Flow Ratio | -26.631 | -10.459 | -1.322 | -0.593 | -6.715 | |
| Debt To Assets Ratio | 0.000 | 0.003 | 0.028 | 0.030 | 0.015 | |
| Debt To Equity Ratio | 0.000 | 0.003 | 0.036 | 0.046 | 0.017 | |
| Debt To Capital Ratio | 0.000 | 0.003 | 0.035 | 0.044 | 0.017 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.068 | 1.085 | 1.262 | 1.513 | 1.167 | |
| Working Capital Turnover Ratio | 0.000 | 0.039 | 0.034 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.167 | -3.509 | -7.057 | -5.388 | -3.241 | |
| Operating Cash Flow Sales Ratio | 0.000 | -15.405 | -45.417 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.002 | 1.008 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -2,264.255 | -96.243 | -44.543 | -52.869 | -28.892 | |
| Capital Expenditure Coverage Ratio | -4,447.643 | 0.000 | -2,222.720 | -416.764 | -118.623 | |
| Dividend Paid And Capex Coverage Ratio | -4,447.643 | 0.000 | -2,222.720 | -416.764 | -118.623 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -20.703 | -6.380 | -0.554 | -0.242 | -4.206 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▲1682.0% | ▲1025.6% |
| Ebit Margin | 0.0% | ▲2137.5% | ▲1435.1% |
| Ebitda Margin | 0.0% | ▲2133.3% | ▲1430.7% |
| Operating Profit Margin | 0.0% | ▲2340.3% | ▲1500.9% |
| Pretax Profit Margin | 0.0% | ▲2137.5% | ▲1435.1% |
| Continuous Operations Profit Margin | 0.0% | ▲2137.5% | ▲1435.1% |
| Net Profit Margin | 0.0% | ▲2137.5% | ▲1435.1% |
| Bottom Line Profit Margin | 0.0% | ▲2137.5% | ▲1435.1% |
| Current Ratio | 10.221 | ▼-0.548 | ▲2.804 |
| Quick Ratio | 10.221 | ▼-0.548 | ▲2.804 |
| Solvency Ratio | -5.072 | ▼-0.227 | ▲0.147 |
| Cash Ratio | 5.978 | ▲0.243 | ▲1.522 |
| Price To Earnings Ratio | -21.865 | ▼-14.327 | ▼-14.641 |
| Price To Earnings Growth Ratio | -0.683 | ▼-0.849 | ▼-0.600 |
| Forward Price To Earnings Growth Ratio | -0.683 | ▼-0.849 | ▼-0.600 |
| Price To Earnings Diluted Ratio | -21.865 | ▼-14.327 | ▼-14.641 |
| Price To Earnings Diluted Growth Ratio | -0.683 | ▼-0.849 | ▼-0.600 |
| Price To Book Ratio | 7.553 | ▲4.460 | ▲4.047 |
| Price To Sales Ratio | 0.000 | ▼-161.126 | ▼-44.233 |
| Price To Free Cash Flow Ratio | -26.625 | ▼-16.166 | ▼-17.494 |
| Price To Operating Cash Flow Ratio | -26.631 | ▼-16.172 | ▼-17.487 |
| Debt To Assets Ratio | 0.000 | ▼-0.003 | ▼-0.015 |
| Debt To Equity Ratio | 0.000 | ▼-0.003 | ▼-0.020 |
| Debt To Capital Ratio | 0.000 | ▼-0.003 | ▼-0.020 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.068 | ▼-0.017 | ▼-0.151 |
| Working Capital Turnover Ratio | 0.000 | ▼-0.039 | ▼-0.015 |
| Operating Cash Flow Ratio | -4.167 | ▼-0.658 | ▲0.505 |
| Operating Cash Flow Sales Ratio | 0.000 | ▲15.405 | ▲12.164 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▲0.000 | ▼-0.002 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -2264.255 | ▼-2168.011 | ▼-1766.894 |
| Capital Expenditure Coverage Ratio | -4447.643 | ▼-4447.643 | ▼-3006.493 |
| Dividend Paid And Capex Coverage Ratio | -4447.643 | ▼-4447.643 | ▼-3006.493 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -20.703 | ▼-14.323 | ▼-14.286 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.63B | $1.38B | $146.9M | $109.7M | $836.3M | |
| Enterprise value | $6.28B | $1.16B | $68.1M | $51.6M | $702.0M | |
| EV / Sales | 0.00x | 136.10x | 27.84x | 0.00x | 0.00x | |
| EV / Op. cash flow | -25.20x | -8.84x | -0.61x | -0.28x | -5.64x | |
| EV / Free cash flow | -25.19x | -8.84x | -0.61x | -0.28x | -5.59x | |
| EV / EBITDA | -20.70x | -6.38x | -0.55x | -0.24x | -4.21x | |
| Net debt / EBITDA | 1.18x | 1.17x | 0.64x | 0.27x | 0.81x | |
| Current ratio | 10.22x | 10.77x | 5.39x | 3.23x | 7.48x | |
| Income quality | 0.82x | 0.72x | 0.90x | 0.86x | 0.75x | |
| Graham net-net | $24 | $20 | $10 | $20 | $83 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $551.1M | $366.8M | $69.1M | $76.5M | $249.0M | |
| Invested capital | $551.4M | $368.2M | $71.8M | $80.4M | $253.8M | |
| Return on assets | -32.3% | -37.8% | -140.2% | -185.9% | -57.1% | |
| Operating ROA | -45.9% | -70.1% | -124.5% | -105.4% | -56.2% | |
| Return on tangible assets | -32.3% | -37.8% | -140.2% | -185.9% | -57.1% | |
| Return on equity | -34.5% | -41.0% | -176.9% | -281.2% | -66.6% | |
| Return on invested capital | -37.1% | -44.8% | -172.3% | -262.9% | -65.6% | |
| Return on capital employed | -37.1% | -44.9% | -175.0% | -266.1% | -65.8% | |
| Earnings yield | -4.6% | -13.3% | -83.9% | -195.1% | -20.0% | |
| Free cash flow yield | -3.8% | -9.6% | -75.7% | -169.1% | -15.0% | |
| Capex / Op. cash flow | -0.0% | 0.0% | -0.0% | -0.2% | -0.8% | |
| Capex / Depreciation | -1.6% | 0.0% | 11.6% | 106.0% | 576.9% | |
| Capex / Sales | 0.0% | 0.0% | 2.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 658.3% | 1718.6% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 1782.0% | 3545.8% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 483.6% | 1015.8% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 64209d | 30d | 24d | 35d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -64209d | -30d | -24d | -35d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-02 Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on October 1, 2026, the Compensation Committee of Praxis'' Board of Directors granted restricted stock unit awards covering an aggregate of 3,478 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees'' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-10-02 Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM) Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends. Analyst Recommendations This is a summary of
- 2026-09-21 Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by Brokerages Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and three have issued a strong buy rating
- 2026-09-12 Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade) Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX''s $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers.
- 2026-09-03 Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis'' Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees'' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-08-27 Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Buy” from Brokerages Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, sixteen have given a buy rating and four have given a
- 2026-08-18 Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High – What’s Next? Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $391.64 and last traded at $376.38, with a volume of 581487 shares traded. The stock had previously closed at $366.81. Analyst Upgrades and Downgrades Several analysts recently weighed
- 2026-08-16 9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB Handelsbanken Fonder AB acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,840 shares of the company''s stock, valued at approximately $3,294,000. Several other hedge funds have also recently
- 2026-08-11 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
- 2026-08-07 Praxis: Commercial Launch Could Smash Expectations (Video) Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa''s commercial launch. I assess PRAX''s strategic positioning and upcoming catalysts tied to Ulixa''s market entry.